332 related articles for article (PubMed ID: 37658562)
1. Theranostic in Nuclear Medicine - The paradigm of NET.
Giammarile F
Hell J Nucl Med; 2023; 26 Suppl():42-43. PubMed ID: 37658562
[TBL] [Abstract][Full Text] [Related]
2. Radiopharmaceuticals used for diagnosis and therapy of NETs.
Papachristou M
Hell J Nucl Med; 2023; 26 Suppl():19-20. PubMed ID: 37658556
[TBL] [Abstract][Full Text] [Related]
3. Tumor imaging and therapy using radiolabeled somatostatin analogues.
de Jong M; Breeman WA; Kwekkeboom DJ; Valkema R; Krenning EP
Acc Chem Res; 2009 Jul; 42(7):873-80. PubMed ID: 19445476
[TBL] [Abstract][Full Text] [Related]
4. Neuroendocrine tumor theranostics.
Ichikawa Y; Kobayashi N; Takano S; Kato I; Endo K; Inoue T
Cancer Sci; 2022 Jun; 113(6):1930-1938. PubMed ID: 35271754
[TBL] [Abstract][Full Text] [Related]
5. Quantitative SPECT/CT for Dosimetry of Peptide Receptor Radionuclide Therapy.
Kennedy J; Chicheportiche A; Keidar Z
Semin Nucl Med; 2022 Mar; 52(2):229-242. PubMed ID: 34911637
[TBL] [Abstract][Full Text] [Related]
6. An Impressive Approach in Nuclear Medicine: Theranostics.
Vahidfar N; Eppard E; Farzanehfar S; Yordanova A; Fallahpoor M; Ahmadzadehfar H
PET Clin; 2021 Jul; 16(3):327-340. PubMed ID: 34053577
[TBL] [Abstract][Full Text] [Related]
7. Consensus on molecular imaging and theranostics in neuroendocrine neoplasms.
Ambrosini V; Kunikowska J; Baudin E; Bodei L; Bouvier C; Capdevila J; Cremonesi M; de Herder WW; Dromain C; Falconi M; Fani M; Fanti S; Hicks RJ; Kabasakal L; Kaltsas G; Lewington V; Minozzi S; Cinquini M; Öberg K; Oyen WJG; O'Toole D; Pavel M; Ruszniewski P; Scarpa A; Strosberg J; Sundin A; Taïeb D; Virgolini I; Wild D; Herrmann K; Yao J
Eur J Cancer; 2021 Mar; 146():56-73. PubMed ID: 33588146
[TBL] [Abstract][Full Text] [Related]
8. Patient selection for personalized peptide receptor radionuclide therapy using Ga-68 somatostatin receptor PET/CT.
Kulkarni HR; Baum RP
PET Clin; 2014 Jan; 9(1):83-90. PubMed ID: 25029937
[TBL] [Abstract][Full Text] [Related]
9. Peptide receptor therapies in neuroendocrine tumors.
Bodei L; Ferone D; Grana CM; Cremonesi M; Signore A; Dierckx RA; Paganelli G
J Endocrinol Invest; 2009 Apr; 32(4):360-9. PubMed ID: 19636207
[TBL] [Abstract][Full Text] [Related]
10. Peptide Receptor Radionuclide Therapy with
Cullinane C; Jeffery CM; Roselt PD; van Dam EM; Jackson S; Kuan K; Jackson P; Binns D; van Zuylekom J; Harris MJ; Hicks RJ; Donnelly PS
J Nucl Med; 2020 Dec; 61(12):1800-1805. PubMed ID: 32414949
[TBL] [Abstract][Full Text] [Related]
11. Receptor radionuclide targeting for neuroendocrine tumors (NET) diagnostic and therapy.
Vija L; Dierickx L; Courbon F
Ann Endocrinol (Paris); 2019 Jun; 80(3):166-171. PubMed ID: 31053248
[TBL] [Abstract][Full Text] [Related]
12. Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog
Zhang J; Wang H; Jacobson O; Cheng Y; Niu G; Li F; Bai C; Zhu Z; Chen X
J Nucl Med; 2018 Nov; 59(11):1699-1705. PubMed ID: 29653971
[TBL] [Abstract][Full Text] [Related]
13. Sequencing of Somatostatin-Receptor-Based Therapies in Neuroendocrine Tumor Patients.
Strosberg JR; Al-Toubah T; El-Haddad G; Reidy Lagunes D; Bodei L
J Nucl Med; 2024 Mar; 65(3):340-348. PubMed ID: 38238038
[TBL] [Abstract][Full Text] [Related]
14. Radiopharmaceuticals for the Diagnosis and Therapy of Neuroendocrine Differentiated Prostate Cancer.
Giovacchini G; Giovannini E; Riondato M; Ciarmiello A
Curr Radiopharm; 2017; 10(1):6-15. PubMed ID: 28034291
[TBL] [Abstract][Full Text] [Related]
15. The Search for an Alternative to [
Waldmann CM; Stuparu AD; van Dam RM; Slavik R
Theranostics; 2019; 9(5):1336-1347. PubMed ID: 30867834
[TBL] [Abstract][Full Text] [Related]
16. Neuroendocrine Tumor Theranostics: An Update and Emerging Applications in Clinical Practice.
Sheikhbahaei S; Sadaghiani MS; Rowe SP; Solnes LB
AJR Am J Roentgenol; 2021 Aug; 217(2):495-506. PubMed ID: 34076455
[No Abstract] [Full Text] [Related]
17. Imaging of neuroendocrine tumors.
Rufini V; Calcagni ML; Baum RP
Semin Nucl Med; 2006 Jul; 36(3):228-47. PubMed ID: 16762613
[TBL] [Abstract][Full Text] [Related]
18. Theranostics with Ga-68 somatostatin receptor PET/CT: monitoring response to peptide receptor radionuclide therapy.
Kulkarni HR; Baum RP
PET Clin; 2014 Jan; 9(1):91-7. PubMed ID: 25029938
[TBL] [Abstract][Full Text] [Related]
19. Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours.
Teunissen JJ; Kwekkeboom DJ; Valkema R; Krenning EP
Endocr Relat Cancer; 2011 Oct; 18 Suppl 1():S27-51. PubMed ID: 22005114
[TBL] [Abstract][Full Text] [Related]
20. Molecular Imaging and Therapy for Neuroendocrine Tumors.
Desai H; Borges-Neto S; Wong TZ
Curr Treat Options Oncol; 2019 Aug; 20(10):78. PubMed ID: 31468190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
